RE: Takeover target at this price.11 Nov 2020 08:54
Profit
Tweet yesterday
We are also on track to make the regulatory submission for the first of Avacta’s revolutionary tumour activated chemotherapies, AVA600 pro-doxorubicin, in 2020 and dose first patients in the UK in early 2021.